Application of size and maturation functions to population pharmacokinetic modeling of pediatric patients

Hyun Moon Back, Jong Bong Lee, Nayoung Han, Sungwoo Goo, Eben Jung, Junyeong Kim, Byungjeong Song, Sook Hee An, Jung Tae Kim, Sandy Jeong Rhie, Yoon Sun Ree, Jung Woo Chae, Jaewoo Kim, Hwi Yeol Yun

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Traditionally, dosage for pediatric patients has been optimized using simple weight-scaled methods, but these methods do not always meet the requirements of children. To overcome this discrepancy, population pharmacokinetic (PK) modeling of size and maturation functions has been proposed. The main objective of the present study was to evaluate a new modeling method for pediatric patients using clinical data from three different clinical studies. To develop the PK models, a nonlinear mixed effect modeling method was employed, and to explore PK differences in pediatric patients, size with allometric and maturation with Michaelis–Menten type functions were evaluated. Goodness of fit plots, visual predictive check and bootstrap were used for model evaluation. Single application of size scaling to PK parameters was statistically significant for the over one year old group. On the other hand, simultaneous use of size and maturation functions was statistically significant for infants younger than one year old. In conclusion, population PK modeling for pediatric patients was successfully performed using clinical data. Size and maturation functions were applied according to established criteria, and single use of size function was applicable for over one year ages, while size and maturation functions were more effective for PK analysis of neonates and infants.

Original languageEnglish
Article number259
Issue number6
StatePublished - Jun 2019


  • Cyclosporin
  • Maturation function
  • Pediatrics
  • Pharmacometrics
  • Phenobarbital
  • Size function
  • Vancomycin


Dive into the research topics of 'Application of size and maturation functions to population pharmacokinetic modeling of pediatric patients'. Together they form a unique fingerprint.

Cite this